Evidence map›Paper›PMID 41963257›Full record

ArticleChemMedChem2026

2-Phenylquinolines Exhibit Anti-Severe Acute Respiratory Syndrome Coronavirus-2 Activity Through the Nonstructural Protein 13 Helicase Inhibition.

Giada Cernicchi, Maria Giulia Nizi, Roberta Emmolo, Leentje Persoons, Manon Laporte, Dirk Jochmans, Isabella Romeo, Giacomo Pepe, Ciro Milite, Pietro Campiglia and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. SARS-CoV-2 NSP8-Derived Peptide Effectively Suppresses the Activity of Helicase NSP13.Computational and structural biotechnology journal · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Giada CernicchiDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Maria Giulia NiziDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Roberta EmmoloDepartment of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italy.
Leentje PersoonsKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Leuven, Belgium.
Manon LaporteKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, Leuven, Belgium.
Dirk JochmansKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, Leuven, Belgium.
Isabella RomeoDepartment of Health Sciences, University of "Magna Græcia" of Catanzaro, Catanzaro, Italy.
Giacomo PepeDepartment of Pharmacy, University of Salerno, Fisciano, Italy.
Ciro MiliteDepartment of Pharmacy, University of Salerno, Fisciano, Italy.
Pietro CampigliaDepartment of Pharmacy, University of Salerno, Fisciano, Italy.
Jacopo SpezziniDepartment of Pharmacy, University of Pisa, Pisa, Italy.
Alma MartelliDepartment of Pharmacy, University of Pisa, Pisa, Italy.
Simone BrogiDepartment of Pharmacy, University of Pisa, Pisa, Italy.
Francesca EspositoDepartment of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italy.
Tommaso FelicettiDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Serena MassariDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Giuseppe ManfroniDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Stefano SabatiniDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Gianluca SbardellaDepartment of Pharmacy, University of Salerno, Fisciano, Italy.
Stefano AlcaroDepartment of Health Sciences, University of "Magna Græcia" of Catanzaro, Catanzaro, Italy.
Johan NeytsKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, Leuven, Belgium.
Angela CoronaDepartment of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italy.
Enzo TramontanoDepartment of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italy.
Steven De JongheKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Molecular, Structural and Translational Virology Research Group, Leuven, Belgium.ORCID https://orcid.org/0000-0002-3872-6558
Oriana TabarriniDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.ORCID https://orcid.org/0000-0003-2693-5675

Funding

Hercules Foundation ZW13-02NextGenerationEU-MUR PNRR INF-ACT Cascade Open Call 2023;COC-1- 2023-CNRPRIN 2022 20228NPP2Y
6 · The paper itself

Abstract

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic has highlighted the fragility of our therapeutic arsenal against human coronaviruses and the urgent need to develop new antivirals. They should exhibit broad-spectrum activity to address future pandemics and target alternative viral proteins to mitigate resistance. We have previously identified a hit compound based on a 2-phenylquinoline scaffold that is able to hinder SARS-CoV-2 replication through nonstructural protein 13 (nsp13) helicase inhibition. Here we reported a SAR study that led to identify new analogs such as 2-(4-butoxyphenyl)-4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethoxy]-5,7-dimethoxyquinoline (14) and 4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethoxy]-2-(4-isopropoxyphenyl)-5,7-dimethoxyquinoline (15), which exhibited a good antiviral profile (EC

Indexed as

Antiviral AgentsQuinolinesRNA HelicasesSARS-CoV-2Viral Nonstructural ProteinsAnimalsCOVID-19 Drug TreatmentHumansMethyltransferasesStructure-Activity RelationshipVirus ReplicationAntiviral AgentsMethyltransferasesNsp13 protein, SARS-CoVQuinolinesRNA HelicasesViral Nonstructural Proteins2‐phenylquinolinesantiviralshuman coronaviruses (HCoVs)nonstructural protein 13 (nsp13) helicasesevere acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

Identifiers

PMID41963257
PMCPMC13068633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.